Zhixiong Li Zhixiong Li

Dr. Zhixiong Li Zhixiong Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
EAEmmanuel Amabebe
Emmanuel Amabebe
ZHZheping Huang
Zheping Huang
SJSukanta Jash
Sukanta Jash
Balaji KrishnanBalaji Krishnan
Balaji Krishnan
SCShibin Cheng
Shibin Cheng
SSSurendra Sharma
Surendra Sharma
Preeclampsia (preE) is a severe multisystem hypertensive syndrome of pregnancy associated with ischemia/hypoxia, angiogenic imbalance, apolipoprotein E (ApoE)-mediated dyslipidemia, placental insufficiency, and inflammation at the maternal–fetal interface. Our recent data further suggest that preE is associated with impaired autophagy, vascular dysfunction, and proteinopathy/tauopathy disorder, similar to neurodegenerative diseases such as Alzheimer’s disease (AD), including the presence of the cis stereo-isoform of phosphorylated tau (cis P-tau), amyloid-β, and transthyretin in the placenta and circulation. This review provides an overview of the factors that may lead to the induction and accumulation of cis P-tau-like proteins by focusing on the inactivation of peptidyl-prolyl cis–trans isomerase (Pin1) that catalyzes the cis to trans isomerization of P-tau. We also highlighted the novel role of the Pin1-cis P-tau-ApoE axis in the development of preE, and propagation of cis P-tau-mediated abnormal protein aggregation (tauopathy) from the placenta to cerebral tissues later in life, leading to neurodegenerative conditions. In the case of preE, proteinopathy/tauopathy may interrupt trophoblast differentiation and induce cell death, similar to the events occurring in neurons. These events may eventually damage the endothelium and cause systemic features of disorders such as preE. Despite impressive research and therapeutic advances in both fields of preE and neurodegenerative diseases, further investigation of Pin1-cis P-tau and ApoE-related mechanistic underpinnings may unravel novel therapeutic options, and new transcriptional and proteomic markers. This review will also cover genetic polymorphisms in the ApoE alleles leading to dyslipidemia induction that may regulate the pathways causing preE or dementia-like features in the reproductive age or later in life, respectively.

12 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
ZLZhixiong Li Zhixiong Li
Zhixiong Li Zhixiong Li
YLYitong Li
Yitong Li
RLRui Liu
Rui Liu
YZYuanming Michelle Zhu
Yuanming Michelle Zhu
RWRuizhi Wang
Ruizhi Wang
XZXiao Zhen Zhou
Xiao Zhen Zhou
Tauopathies comprise a heterogeneous group of neurological and systemic disorders characterized by pathological tau dysregulation, traditionally including Alzheimer’s disease (AD), traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE). Emerging evidence suggests that tauopathy may also occur in selected vascular and systemic disease contexts, including ischemic stroke, vascular dementia (VaD), and preeclampsia (PE), although the strength and clinical significance of this evidence vary among these conditions. Compelling evidence suggests that the Pin1-cis phosphorylated tau (cis P-tau) axis may represent a convergent molecular mechanism linking these conditions. Pin1 is a phosphorylation-specific peptidyl-prolyl cis-trans isomerase that protects against tauopathy and cognitive impairment by catalyzing conversion of pathological cis P-tau to the physiological trans conformation at phosphorylated Thr231-Pro motifs. Under stress conditions such as oxidative stress, hypoxia, inflammation, mechanical injury, or aging, Pin1 activity becomes impaired through oxidation, phosphorylation, sequestration, or transcriptional downregulation, resulting in the accumulation of neurotoxic cis P-tau. cis P-tau is proposed to initiate a pathogenic cascade termed cistauosis in neurons, characterized by axonal microtubule collapse and transport failure, mitochondrial dysfunction, synaptic degeneration, neuroinflammation, neuronal death, and prion-like spread. Importantly, cis P-tau appears rapidly after insults long before overt neurofibrillary tangle (NFT) formation in several experimental and clinical contexts, supporting its role as an upstream pathogenic driver and early biomarker. Crucially, conformation-specific monoclonal antibodies targeting cis P-tau selectively eliminate pathological cis P-tau while sparing physiological trans P-tau, demonstrating promising therapeutic effects in preclinical models of TBI, vascular injury, AD-related tauopathy, and PE. This review summarizes the molecular basis of the Pin1–cis P-tau axis, examines its role across conventional and unconventional tauopathies, evaluates its biomarker potential, and highlights cis-specific immunotherapy as a potentially broad therapeutic strategy for neurodegenerative, traumatic, and vascular cognitive disorders.